Literature DB >> 21591544

Therapeutic advances in cutaneous T-cell lymphoma.

Oleg E Akilov1, Larisa Geskin.   

Abstract

A variety of novel therapeutic modalities have recently become available for patients with cutaneous T cell lymphoma (CTCL). In particular, with recent FDA approvals of the three new agents vorinostat (Zolinza), romidepsin (Istodax), and pralatrexate (Folotyn) CTCL treatment has been transformed. Here, we offer a brief overview of these agents and discuss their place in the spectrum of current therapies for CTCL.

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21591544      PMCID： PMC3954531     

Source DB:  PubMed          Journal:  Skin Therapy Lett        ISSN： 1201-5989


  32 in total

1.  Action of FR901228, a novel antitumor bicyclic depsipeptide produced by Chromobacterium violaceum no. 968, on Ha-ras transformed NIH3T3 cells.

Authors:  H Ueda; H Nakajima; Y Hori; T Goto; M Okuhara
Journal:  Biosci Biotechnol Biochem       Date:  1994-09       Impact factor: 2.043

Review 2.  Pralatrexate: an emerging new agent with activity in T-cell lymphomas.

Authors:  Owen A O'Connor
Journal:  Curr Opin Oncol       Date:  2006-11       Impact factor: 3.645

3.  Autologous bone marrow transplantation for advanced stage mycosis fungoides.

Authors:  R D Bigler; P Crilley; B Micaily; L W Brady; D Topolsky; S Bulova; E C Vonderheid; I Brodsky
Journal:  Bone Marrow Transplant       Date:  1991-02       Impact factor: 5.483

4.  Vorinostat for treatment of cutaneous manifestations of advanced primary cutaneous T-cell lymphoma.

Authors:  Bhupinder S Mann; John R Johnson; Kun He; Rajeshwari Sridhara; Sophia Abraham; Brian P Booth; Leigh Verbois; David E Morse; Josephine M Jee; Sarah Pope; Ravi S Harapanhalli; Ramzi Dagher; Ann Farrell; Robert Justice; Richard Pazdur
Journal:  Clin Cancer Res       Date:  2007-04-15       Impact factor: 12.531

Review 5.  Mycosis fungoides and the Sézary syndrome.

Authors:  Y H Kim; R T Hoppe
Journal:  Semin Oncol       Date:  1999-06       Impact factor: 4.929

Review 6.  WHO-EORTC classification for cutaneous lymphomas.

Authors:  Rein Willemze; Elaine S Jaffe; Günter Burg; Lorenzo Cerroni; Emilio Berti; Steven H Swerdlow; Elisabeth Ralfkiaer; Sergio Chimenti; José L Diaz-Perez; Lyn M Duncan; Florent Grange; Nancy Lee Harris; Werner Kempf; Helmut Kerl; Michael Kurrer; Robert Knobler; Nicola Pimpinelli; Christian Sander; Marco Santucci; Wolfram Sterry; Maarten H Vermeer; Janine Wechsler; Sean Whittaker; Chris J L M Meijer
Journal:  Blood       Date:  2005-02-03       Impact factor: 22.113

7.  Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma.

Authors:  Elise A Olsen; Youn H Kim; Timothy M Kuzel; Theresa R Pacheco; Francine M Foss; Sareeta Parker; Stanley R Frankel; Cong Chen; Justin L Ricker; Jean Marie Arduino; Madeleine Duvic
Journal:  J Clin Oncol       Date:  2007-06-18       Impact factor: 44.544

8.  Low-dose intermittent alemtuzumab in the treatment of Sézary syndrome: clinical and immunologic findings in 14 patients.

Authors:  Maria Grazia Bernengo; Pietro Quaglino; Alessandra Comessatti; Michela Ortoncelli; Mauro Novelli; Francesco Lisa; Maria Teresa Fierro
Journal:  Haematologica       Date:  2007-06       Impact factor: 9.941

9.  Tacrolimus ointment does not affect collagen synthesis: results of a single-center randomized trial.

Authors:  S Reitamo; J Rissanen; A Remitz; H Granlund; P Erkko; P Elg; P Autio; A I Lauerma
Journal:  J Invest Dermatol       Date:  1998-09       Impact factor: 8.551

10.  The role of transferrin receptor (CD71) in photodynamic therapy of activated and malignant lymphocytes using the heme precursor delta-aminolevulinic acid (ALA).

Authors:  K Rittenhouse-Diakun; H Van Leengoed; J Morgan; E Hryhorenko; G Paszkiewicz; J E Whitaker; A R Oseroff
Journal:  Photochem Photobiol       Date:  1995-05       Impact factor: 3.421
View more
  5 in total

1.  Regulation of HLA-DR peptide occupancy by histone deacetylase inhibitors.

Authors:  Kevin Cronin; Hernando Escobar; Karoly Szekeres; Eduardo Reyes-Vargas; Alan L Rockwood; Mark C Lloyd; Julio C Delgado; George Blanck
Journal:  Hum Vaccin Immunother       Date:  2013-01-17       Impact factor: 3.452

Review 2.  New Therapies and Immunological Findings in Cutaneous T-Cell Lymphoma.

Authors:  Kazuyasu Fujii
Journal:  Front Oncol       Date:  2018-06-04       Impact factor: 6.244

3.  Functional Depletion of HSP72 by siRNA and Quercetin Enhances Vorinostat-Induced Apoptosis in an HSP72-Overexpressing Cutaneous T-Cell Lymphoma Cell Line, Hut78.

Authors:  Kazuyasu Fujii; Masashi Idogawa; Norihiro Suzuki; Keiji Iwatsuki; Takuro Kanekura
Journal:  Int J Mol Sci       Date:  2021-10-19       Impact factor: 5.923

4.  Vorinostat approved in Japan for treatment of cutaneous T-cell lymphomas: status and prospects.

Authors:  Akinori Sato
Journal:  Onco Targets Ther       Date:  2012-04-27       Impact factor: 4.147

5.  Therapeutic effects of topical 0.03% Tacrolimus ointment in children with refractory vernal keratoconjunctivitis in Middle East.

Authors:  Sandra Flavia Fiorentini; Darakhshanda Khurram
Journal:  Saudi J Ophthalmol       Date:  2019-05-17
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.